Considerable research effort has been made worldwide to decipher the immune response
triggered upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections …

The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage 1. The receptor …

Monoclonal Antibody and Antiviral Activity against Omicron Investigators assessed the in
vitro activities of seven monoclonal antibodies and three antiviral drugs against Covid-19 …

The continuing emergence of SARS-CoV-2 variants highlights the need to update COVID-19
vaccine compositions. However, immune imprinting induced by vaccination based on the …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of
concern evades antibody-mediated immunity that comes from vaccination or infection with …

During the current coronavirus disease 2019 (COVID-19) pandemic, a variety of mutations
have accumulated in the viral genome of severe acute respiratory syndrome coronavirus 2 …

As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of
concern comprises several sublineages, with BA. 2 and BA. 2.12. 1 having replaced the …

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape,–, have activity
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …